Data
Immunoblotting: use at 1-5ug/ml. A band of ~131kDa is detected. IP western blot analysis was performed on human leukemia cell lines that harbor MLL chromosomal translocations and express MLL chimeric oncoproteins (indicated at tops). IP was performed with the antibodies indicated on the top of the gels - -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Immunogen Maltose-binding fusion protein containing AF4 amino acids 782-979 (Accession no. NP_005926). Product Concentration Lot Specific Formulation This monoclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.2 - 7.4 with no carrier protein or preservatives added. State of Matter Liquid Product Preparation Antibodies are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling This antibody is stable for at least one (1) year at -20°C. Avoid multiple freeze-thaw cycles. Country of Origin USA Shipping Next Day 2-8°C Applications and Recommended Usage? Quality Tested by Leinco Immunoblotting: use at 1-5ug/mL. A band of ~131kDa is detected.IP western blot analysis was performed on human leukemia cell lines that harbor MLL chromosomal translocations and express MLL chimeric oncoproteins (indicated at tops). IP was performed with the antibodies indicated on the top of the gels, and the precipitates were immunoblotted with the antibodies indicated on the right. Antibody #34042 is shown as AF4. Anti-GST antibodies served as negative controls.
Positive control: K562 cell lysates. These are recommended concentrations. Endusers should determine optimal concentrations for their applications. Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This antibody recognizes human AF4. Background The AF4 and ENL (Eleven nineteen Leukemia) protein families are the most frequent MLL fusion partners accounting for two-thirds of MLL-associated leukemia incidence. AF4 (also known as FEL) is a gene which was first described as a fusion partner with MLL in the t(4;11) acute leukemia. Based on analysis by Northern blotting, AF4 mRNAs were found to be widely expressed in hematopoietic cells and normal human tissues. cDNA sequence analysis of the AF4 gene showed that it encodes a serine/proline-rich protein with a predicted size of 130-140kDa containing guanosine triphosphate (GTP)-binding and putative nuclear-localization sequences. Studies have demonstrated that a related gene, LAF4, isolated from Burkitt's lymphoma, shares high degree of sequence homology with AF4. LAF4 was shown to possess DNA binding ability and transcriptional activation potential. Both AF4 and LAF4 were shown to be evolutionary conserved in vertebrates suggesting an important functional role of the genes. NCBI Gene Bank ID UniProt.org Research Area Cancer Research References & CitationsYokoyama A et al. 2010 Cancer Cell 17: 198-212. Technical Protocols Certificate of Analysis |
Formats Available
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
